LGLucy Godson

Lucy Godson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lucy Godson has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    AI in Cancer Prognosis: A Systematic Review of Multimodal Models Combining Pathology Images and High-Throughput Omics

    by Charlotte Jennings, Andrew Broad, Lucy Godson, Emily Clarke, David Westhead, Darren Treanor

    This study systematically reviews and evaluates published research on machine learning models that integrate histopathology whole slide images and high-throughput -omic data to predict overall survival in cancer. A comprehensive search of PubMed, EMBASE, and Cochrane CENTRAL was conducted through August 12, 2024, with citation screening for additional studies. Eligible studies applied machine learning or deep learning methods to multimodal data combining pathology images and -omics. Data extraction followed the CHARMS checklist, and risk of bias was assessed using the PROBAST + AI tool. Narrative synthesis was conducted in line with PRISMA 2020 guidelines. Forty-eight studies published since 2017 met inclusion criteria, spanning 19 cancer types. All relied on The Cancer Genome Atlas dataset. Modelling approaches included regularised Cox regression (n = 4), classical machine learning (n = 13), and deep learning (n = 31). Reported concordance indices ranged from 0.550 to 0.857, with most multimodal models outperforming unimodal counterparts. However, all studies were assessed as having high or unclear risk of bias—most often due to limited external validation, insufficient reporting, and minimal assessment of clinical utility. This review highlights a rapidly evolving yet methodologically underdeveloped field. While model performance is promising, improvements in data standardisation, reporting practices, and real-world contextualisation are critical for clinical translation. This work was funded by the National Pathology Imaging Cooperative (NPIC), supported by UK Research and Innovation (Project no. 104687).


  • Open Access

    Artificial Intelligence Devices for Image Analysis in Digital Pathology

    by Ga Matthews, Lucy Godson, Clare McGenity, Daljeet Bansal, Darren Treanor, Gillian A Matthews

    B ackground: There is increasing momentum behind the clinical implementation of AI-based software for image analysis in digital pathology. As regulations, standards, and national approaches to the clinical use of AI continue to develop, the marketplace of AI products is expanding and evolving – presenting pathologists with a multitude of devices that offer the potential to improve pathology services. M ethods: To maintain pace with this changing AI device landscape, we conducted a comprehensive search for, and analysis of, commercial AI products for image analysis in digital pathology. This included CE-marked and Research Use Only (RUO) products using images with histological stains (e.g., H&E) or immunohistochemical (IHC) labelling. Product information and published clinical validation studies were assessed, to understand the quality of supporting evidence on available products, and product details were compiled into a public register: https://osf.io/gb84r/overview . R esults: In total, we identified and assessed 90 CE-marked and 227 RUO AI products. We found that AI products for cancer detection in prostate and breast pathology comprised a substantial portion of the marketplace for H&E image analysis, while IHC products were almost exclusively for use in breast cancer. Clinical validation studies on these products have steadily increased; however, we found that published studies were only available for just over half of H&E products and just over a quarter of IHC products. For CE-marked products, the dataset quality and diversity for AI model performance validation was highly variable, and particularly limited for IHC products. Furthermore, only a limited number of products included studies that assessed measures of clinical utility. C onclusion: As clinical deployment of AI products for image analysis in histopathology grows, there is a need for transparency, rigorous validation, and clear evidence supporting clinical utility and cost-effectiveness. Independent scrutiny of the expanding offering of AI products provides insight into the opportunities and shortcomings in this domain.

  • Multi-level Graph Representations of Melanoma Whole Slide Images for Identifying Immune Subgroups

    by Lucy Godson, Navid Alemi, Jérémie Nsengimana, Graham P. Cook, Emily L. Clarke, Darren Treanor, D. Timothy Bishop, Julia Newton-Bishop, Derek Magee


  • Open Access

    Immune subtyping of melanoma whole slide images using multiple instance learning

    by Lucy Godson, Navid Alemi, Jérémie Nsengimana, Graham P. Cook, Emily L. Clarke, Darren Treanor, D. Timothy Bishop, Julia Newton-Bishop, Ali Gooya, Derek Magee